Pelvic floor dysfunction

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Retrieved on: 
水曜日, 1月 17, 2024
Mortality, Death, Patient, Incidence, ICU, Cytokine adsorbing column, Vasoplegic syndrome, Semmelweis University, Professional corporation, DRS, European Society of Cardiology, RCT, Heart, Standard of care, Pelvic floor dysfunction, Cytosorbents Corporation, Circulatory system, Risk, Organ dysfunction, VS, Multiple organ dysfunction syndrome, Observational study, Shock, Randomized controlled trial, ESC, Dentistry

In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.

Key Points: 
  • In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.
  • In a prior observational study , CytoSorb was associated with the reduced severity of vasoplegia in heart transplant patients, in addition to other clinical benefits.
  • In this prospective, single-center, open-label RCT, 60 heart transplant recipients were randomly assigned to either receive intraoperative CytoSorb hemoadsorption or standard of care.
  • Now, Nemeth, Soltesz, and colleagues have confirmed many of these observations in this rigorous and well-designed groundbreaking randomized controlled trial in orthotopic heart transplant patients.

eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor

Retrieved on: 
木曜日, 1月 18, 2024
Other Health, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hospitals, Genetics, Data Management, Science, Technology, Veterinary, Clinical Trials, General Health, FDA, Biotechnology, Surgery, Health, Mortality, Hope, Family, Patient, Coagulation, Liver failure, Multimedia, ELC, MFS, Pelvic floor dysfunction, Gift, Gene, University, Drug discovery, Risk, Perfusion, Transgene, IND, Food, Pressure, Liver, Inflammation, Genome, Organization, CPTC, Bile, Cell, Trial of the century, Dietary supplement

The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.

Key Points: 
  • The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
  • The efficacy of existing liver support options is limited, and patients in liver failure face a high risk of mortality.
  • For some patients, utilizing a human-compatible, genetically engineered porcine whole liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant.
  • The genetically engineered porcine liver used in this study carried the same genetics as the porcine kidneys used in the landmark preclinical study recently published in Nature .

American Nurses Foundation Launches New Campaign to Reshape Healthcare Through the Power of Nursing

Retrieved on: 
月曜日, 1月 8, 2024
Omnicell, Dementia, American Nurses Foundation, University, Pelvic floor dysfunction, Movement, Spring, Health, Nursing, Patient, Intelligence

Silver Spring, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The American Nurses Foundation (the Foundation) has launched Count Me In , a national campaign with a clarion call to join nurses in reshaping health care through the power of nursing.

Key Points: 
  • Silver Spring, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The American Nurses Foundation (the Foundation) has launched Count Me In , a national campaign with a clarion call to join nurses in reshaping health care through the power of nursing.
  • “Genuine support of this nurse-led movement is a simple and impactful way to join nurses across the country in repairing our broken health care system,” said American Nurses Foundation Executive Director Kate Judge.
  • “The Foundation is forever grateful for the generosity of our funders and their commitment to nursing,” said Judge.
  • The Reimagining Nursing Initiative is made possible through generous the generous support of the Kaiser Permanente National Community Benefit Fund at East Bay Community Foundation, AMN Healthcare, Omnicell, and the Salka Impact Fund.

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
火曜日, 1月 2, 2024
Fungal infection, Medical Subject Headings, Marketing, European Commission, Liver, INN, Nitrate, Woman, Allergy, PDE5, Pelvic floor dysfunction, ATC, Hypotension, Itraconazole, International, Man, European, Headache, Ageing, Language, Blood, CGMP, Mouth, Eye, Pulmonary hypertension, Erectile dysfunction, Stroke, Kidney, Kidney disease, Angina, Ketoconazole, HIV, Ritonavir, Tablet, Indinavir, Select, Committee, Patient, Penis, Liver disease, Risk management, Anatomy, Medicine, Dialysis, IIA, Diabetes, CHMP, Medical device

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

ArrivoBio Raises $45M in Series B Financing to Advance Pipeline

Retrieved on: 
水曜日, 11月 29, 2023
Mental Health, Health, General Health, Clinical Trials, Research, Science, Biotechnology, DNA, DSM-IV codes, Grammatical mood, Patient, Pelvic floor dysfunction, Male, Metabolism, FDA, Fat necrosis, Gene expression, Series, Acute pancreatitis, DNA repair, SIRT6, Death, Pancreatitis, Female, MDD, Pharmaceutical industry, Arrivo

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.

Key Points: 
  • Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.
  • “We are extremely grateful to our investors who continue to believe in our team and our promising pipeline,” said Steve Butts, CEO of Arrivo.
  • Orlando Health Ventures led the Series B financing with additional investment from Solas BioVentures Emerging Healthcare Fund, L.P., Rex Health Ventures and several private investors.
  • “Oversubscribed capital fundraising is rare in today’s market, and today’s Series B closing is a testament to the strong data behind both pipeline treatments, SP-624 and RABI-767, which have the potential to change millions of patients’ lives.”

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
水曜日, 11月 29, 2023
Health, Medical Devices, Infectious Diseases, COVID-19, Research, Science, Biotechnology, Karolinska Institute, DRS, Cytokine, Biomedical engineering, Interface (computing), Brain, Journal of Internal Medicine, Inflammatory Bowel Diseases, Disease, Homeostasis, Patient, Multimedia, Journal, Pelvic floor dysfunction, Pulmonary hypertension, Rheumatoid arthritis, Nervous system, Heart rate, Arthritis, Internal medicine, JIM, Neuroscience, Medical research, Molecular medicine, Paralysis, Periodic breathing, Credit, Cancer, Acetylcholine, Famotidine, VNS, Doctor of Philosophy, Sensation, SARS-CoV-2, Diabetes, Outline, Inflammation, Vagus nerve, HMGB1, Pharmaceutical industry, MD

View the full release here: https://www.businesswire.com/news/home/20231129335345/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

INTIMINA Calls for Increased Pelvic Floor Health Awareness and Patient Advocacy as Vital Wellness Trends in 2024

Retrieved on: 
火曜日, 11月 28, 2023
Women, Other Retail, Fitness & Nutrition, LGBTQ+, Specialty, Physical Therapy, General Health, Consumer, Health, Retail, Communication, Empowerment, Woman, Incontinence, Social stigma, Pelvic floor, American Physical Therapy Association, Knowledge, Pelvic floor dysfunction, Education, Trust, Nursing, Birth control

INTIMINA , a leading intimate health brand, is urging women to make pelvic floor health and patient advocacy a key priority in 2024 and beyond.

Key Points: 
  • INTIMINA , a leading intimate health brand, is urging women to make pelvic floor health and patient advocacy a key priority in 2024 and beyond.
  • As holistic wellness continues to gain mainstream interest, INTIMINA recognizes that pelvic floor health, education and empowerment must be an integral part of the holistic health conversation.
  • Recognizing the urgency of addressing these concerns, health professionals are stressing the need for proactive steps towards pelvic floor wellness.
  • INTIMINA is committed to changing the lack of transparency and stigmatization around pelvic floor health by focusing on knowledge, advocacy, transparency and proactivity.

Artificial Organs Global Market Report 2023: A Potential $17.7 Billion Opportunity by 2027 - Benefits of Artificial Organs Over Traditional Transplants Drive Market Expansion - ResearchAndMarkets.com

Retrieved on: 
月曜日, 11月 13, 2023
Hospitals, Health, Surgery, Medical Supplies, Kidney disease, COPD, Artificial organ, Prevalence, Cardiomyopathy, Investment, Liver cancer, Pelvic floor dysfunction, End organ damage, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Viral, Inflammation, Chronic obstructive pulmonary disease, Blood, Organ transplantation, Ageing, Infection, Myocarditis, Growth, Cystic fibrosis, Moyamoya disease, Organic, Accident, Sonova, LivaNova, Smoking, Blood pressure, Aquaculture, Dentistry

This report is a comprehensive study of the global artificial organs market.

Key Points: 
  • This report is a comprehensive study of the global artificial organs market.
  • It describes the artificial organs market, segmented by product type and region.
  • Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants.
  • Emerge more prepared and stay at the forefront of the global artificial organs market.

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Retrieved on: 
水曜日, 11月 1, 2023
Cream, Desire, Female, FDA, Trial of the century, SST, Food, Diagnostic and Statistical Manual of Mental Disorders, Endpoint, Diagnosis, DSM-IV codes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pelvic floor dysfunction, Embarrassment, Guilt, Female sexual arousal disorder, Arousal, FSAD, Woman, DSM-IV, PRO, Pharmaceutical industry

The Phase 2b RESPOND study enrolled women with FSAD and included women who had sexual dysfunctions in addition to FSAD.

Key Points: 
  • The Phase 2b RESPOND study enrolled women with FSAD and included women who had sexual dysfunctions in addition to FSAD.
  • In addition, only the Sildenafil Cream treatment group in this subset, and not the placebo group, demonstrated clinically meaningful improvement at the end of the 12-week period.
  • “The further analyses bolster our belief that Sildenafil Cream has the potential to successfully address the significant unmet need of arousal disorder.
  • The Phase 3 study design for Sildenafil Cream, including primary and secondary efficacy endpoints and inclusion/exclusion criteria for study participants, will be determined following discussions with the U.S. Food and Drug Administration (FDA), including the company’s end of Phase 2 meeting with the FDA.

eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference

Retrieved on: 
木曜日, 10月 26, 2023
Massachusetts General Hospital, Survival, RNA, Antigen, CRISPR, Cell Transplantation, Organ dysfunction, Kidney, Cell, Pelvic floor dysfunction, Transgene, System, Organ transplantation, Risk, Congress, Complement, Gene, Endothelium, Transplant, Patient, NHP, Ischemia, Pharmaceutical industry, Dentistry, Vaccine, Nature

Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.

Key Points: 
  • Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
  • A third presentation will share the results of a study evaluating pancreatic islets from genetically engineered porcine donors transplanted into a mouse model.
  • “We’re thrilled to share data highlighting our lead candidate for kidney transplant, EGEN-2784, as well as additional data supporting our genome engineering platform.
  • Humanized porcine donors were genetically engineered using the Yucatan miniature pig breed to carry 69 genomic edits through CRISPR/Cas 9 technology.